Supplementary Figure 6 from The CCL17–CCR4 Axis Is Critical for Mutant STAT6-Mediated Microenvironmental Remodeling and Therapeutic Resistance in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Madelyn Jean Abraham; Cynthia Guilbert; Natascha Gagnon; Christophe Gonçalves; Alexandre Benoit; Kelly Tran; Owen Hiltebrand; Ryan N. Rys; Samuel E.J. Preston; Ryan D. Morin; Wilson H. Miller; Nathalie A. Johnson; Sonia V. del Rincon; Koren Kathleen Mann

doi:10.1158/2326-6066.31484390

Supplementary Figure 6 from The CCL17–CCR4 Axis Is Critical for Mutant STAT6-Mediated Microenvironmental Remodeling and Therapeutic Resistance in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

2026 Open access

Read full text

Authors: Madelyn Jean Abraham, Cynthia Guilbert, Natascha Gagnon, Christophe Gonçalves, Alexandre Benoit, Kelly Tran, Owen Hiltebrand, Ryan N. Rys, Samuel E.J. Preston, Ryan D. Morin, Wilson H. Miller, Nathalie A. Johnson

+2 more

Sonia V. del Rincon, Koren Kathleen Mann

DOI: 10.1158/2326-6066.31484390

Cited by: 0

Abstract

mSTAT6WT and mSTAT6D419N Eµ-Myc tumors have no difference in tumor burden or expression of CD4+ and CD8+ T-cells, following relapse from doxorubicin treatment.

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research Chemokine receptors and signaling

Publication details

Publication date: 4 March 2026
Language: EN